Business Context and Reporting Period
Pliant Therapeutics, Inc. (PLRX) is a clinical-stage biopharmaceutical company focused on developing integrin-based therapeutics. The reporting period covers the quarter and six months ended June 30, 2026. The Company's lead program, PLN-101095, is an oral small molecule inhibitor in Phase 1b development for solid tumors. In 2025, the Company discontinued the development of bexotegrast for Idiopathic Pulmonary Fibrosis (IPF) following unfavorable safety data, leading to a strategic refocusing of resources and a significant restructuring of operations.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 | Six Months Ended June 30, 2026 | As of June 30, 2026 |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(22,371) | $(42,411) | N/A |
| Net Loss Per Share (Basic & Diluted) | $(0.36) | $(0.69) | N/A |
| Research & Development Expenses | $(16,727) | $(30,311) | N/A |
| General & Administrative Expenses | $(7,135) | $(15,323) | N/A |
| Cash, Cash Equivalents & Short-Term Investments | N/A | N/A | $158,101 |
| Accumulated Deficit | N/A | N/A | $(901,807) |
| Long-Term Debt | N/A | N/A | $0 |
Note: The Company has no revenue and continues to incur significant operating losses. Cash and cash equivalents were $24,883 and short-term investments were $133,218 as of June 30, 2026.
Material Changes vs. Prior Period
- Expense Reduction: Total operating expenses decreased by $21.7 million for the three months ended June 30, 2026, compared to the same period in 2025. This was driven primarily by the discontinuation of the bexotegrast program and a reduction in headcount following the 2025 restructuring.
- R&D Shift: While total R&D expenses declined, program-specific external expenses for the lead candidate PLN-101095 increased by $8.3 million year-over-year, reflecting the reprioritization of the pipeline.
- Debt Elimination: The Company fully repaid its term loan with Oxford Finance LLC in October 2025. Consequently, there was no interest expense in the current period, compared to $0.8 million in the prior year quarter.
- Cash Flow: Net cash used in operating activities decreased significantly to $32.0 million for the six months ended June 30, 2026, from $89.5 million in the prior year period, due to lower operating costs and the cessation of the BEACON-IPF trial.
Guidance, Outlook, and Risks
Outlook and Management Commentary: Management expects to continue incurring net losses for the foreseeable future. The Company believes its existing capital resources ($159.6 million in cash and investments) are sufficient to fund operations for at least the next 12 months. The focus remains on advancing PLN-101095, with the FORTIFY Phase 1b trial enrollment progressing ahead of schedule. Interim data is expected in 2027. The Company also continues to explore its integrin-targeted drug delivery platform.
Key Risks and Contingencies:
- Capital Requirements: Substantial additional capital will be required to complete clinical development and commercialization. Failure to raise funds could force delays or elimination of programs.
- Supply Chain & Geopolitics: The Company relies on third-party manufacturers, including vendors in China (e.g., WuXi AppTec). The "BIOSECURE Act" and potential designation of Chinese entities as "biotechnology companies of concern" pose risks of supply interruption or forced restructuring of manufacturing arrangements.
- Stock-Based Compensation: In April 2026, the Company repriced outstanding stock options to $1.33 per share, resulting in an incremental expense of $2.0 million to be recognized over 1.37 years.
- Regulatory & Clinical Risk: As a clinical-stage company with no approved products, success is highly dependent on the safety and efficacy of PLN-101095. Previous failures (bexotegrast) highlight the uncertainty of clinical development.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $159.6 million cash balance against the projected burn rate for the PLN-101095 Phase 1b and subsequent trials.
- Manufacturing Dependencies: Assess the specific exposure to Chinese vendors (WuXi AppTec) and the Company's contingency plans regarding the BIOSECURE Act and potential supply chain disruptions.
- Option Repricing Impact: Review the dilution effects and future expense recognition associated with the April 2026 stock option repricing.
- Clinical Progress: Monitor enrollment rates and safety data for the FORTIFY Phase 1b trial, as this is the primary value driver.
- At-The-Market Offering: Note the existence of a Sales Agreement with Leerink Partners allowing for the sale of up to $50.0 million of common stock, which could lead to future dilution.